Similarly, heterodimerization of D1 and D2 dopamine receptors alters ligand selectivity and signaling outcomes, offering new therapeutic opportunities for neurological disorders, such as post-traumatic stress disorder (PTSD) and Parkinson’s disease [89]. This evidence concerns the gene DRD2 and Parkinson disease.